A clinical exome test sequences the protein-coding parts of the genome (exons) to identify genetic variants that cause inherited diseases. It examines thousands of genes to diagnose unexplained developmental delay, congenital anomalies, epilepsy, and other suspected Mendelian disorders. It detects single-nucleotide changes, small indels and some copy-number changes but may miss deep intronic, epigenetic, or certain structural variants; interpretation and genetic counseling are recommended.

Clinical exome testing typically costs about $300–$3,000 when ordered privately. Prices vary by country, laboratory, whether trio testing (parents plus child) or extra interpretation is needed, and whether insurance or public health programs cover it—some patients get testing with little or no direct cost. Check with your clinician or the testing lab for an exact, itemized estimate.

Exome testing sequences all protein-coding regions of genes to detect variants that cause or contribute to disease. It’s used to diagnose rare or undiagnosed genetic conditions (developmental delay, congenital anomalies, epilepsy), clarify unclear clinical presentations, guide treatment and prognosis, inform reproductive decisions and carrier status, and support targeted therapies or clinical trial eligibility. Results also aid family planning and cascade testing.

Exome sequencing can detect pathogenic single‑gene (Mendelian) variants causing many inherited disorders—e.g., cystic fibrosis, Duchenne muscular dystrophy, phenylketonuria, Marfan syndrome, familial hypercholesterolemia, Charcot‑Marie‑Tooth, hereditary breast/ovarian cancer (BRCA), primary immunodeficiencies, developmental delay/intellectual disability, epileptic encephalopathies, cardiomyopathies and many metabolic disorders. It’s best for SNVs and small indels; some structural variants, repeat expansions and mitochondrial or noncoding changes may be missed.

Exome sequencing typically takes several weeks to months. Routine diagnostic exomes usually return results in about 6–12 weeks; trio testing can be quicker (about 4–8 weeks). Rapid protocols for critically ill patients may deliver findings within 1–3 weeks. Total turnaround depends on sample logistics, laboratory workload, depth of analysis, need for parental samples, variant confirmation, and specialist interpretation.

Exome sequencing is less costly than whole-genome sequencing but still moderately expensive. Prices vary by country and setting: research tests and targeted panels are cheaper, while clinical diagnostic exomes (especially trio testing) can cost hundreds to a few thousand dollars. Insurance or public health systems sometimes cover clinically indicated tests, reducing out-of-pocket costs. Interpretation and turnaround time also add to total expense.